Download the Visual
In obesity, access has replaced efficacy as the constraint on value
Beating the weight loss of today’s injectable GLP-1s is no longer enough on its own for a new obesity drug, because access, not efficacy, has become the binding constraint on value. In Sleuth’s December 2025 analysis of 174 Phase 2 and later obesity assets, the drugs positioned to shape the market are the ones that sit on or push out an access–efficacy frontier.
Injectable GLP-1s have set a de-risked efficacy benchmark across several molecules and sponsors. It is not a hard ceiling, but it moves the question from whether meaningful weight loss is achievable to how it can be delivered, accessed and paid for at scale. A more effective injectable still faces the payer scrutiny, access friction and incumbency advantages that constrain today’s GLP-1s.
Sleuth placed 174 assets on expected efficacy and patient and payer access
Each asset sits on two composite scores. Expected efficacy potential combines mechanism class, incretin co-agonism and clinical maturity, and the patient and payer access score combines route of administration, dosing frequency and inferred cost tier. The chart shows relative placement, not precise measurement.
Injectable GLP-1 backbones, including tirzepatide, semaglutide, survodutide, retatrutide and cagrilintide with semaglutide (CagriSema), cluster at high efficacy but low-to-medium access. Oral orforglipron and Rybelsus (oral semaglutide) sit just past the midpoint on access and around the midpoint on efficacy. Orlistat, orlistat with acarbose and the Plenity device sit at medium to higher access but low efficacy, and assets low on both axes fall into a zone Sleuth labels structurally unattractive. Only a handful of assets reached the high-efficacy, high-access quadrant, which the chart labels for oral GLP-1s and next-generation combinations, and none sat far past the midpoints.
In Sleuth’s reading, late-stage capital, BD interest and pharma portfolio focus cluster around assets on or near the frontier, while assets far from it face structural commercial headwinds whatever their scientific novelty.
Oral GLP-1s expand the frontier toward access
Oral programs such as Lilly’s orforglipron and the tablet form of Viking’s VK2735, a GLP-1 and GIP dual agonist, push the frontier horizontally. Not every oral is patient-friendly, but select programs relax specific access constraints while staying close to the injectable efficacy benchmark, and in a payer-managed category access friction often becomes the binding constraint once efficacy is de-risked.
After this analysis, the FDA approved orforglipron as Foundayo on April 1, 2026, following Novo Nordisk’s Wegovy pill (oral semaglutide) in December 2025. On July 1, 2026, a Medicare GLP-1 Bridge pilot began covering Wegovy, Zepbound and Foundayo for a flat $50 copay per prescription. Sleuth’s Q3 2026 GLP-1 Intelligence Report covers the early oral launches.
An oral does not need to win on weight loss to matter. It needs to stay near the efficacy benchmark while making the drug easier to prescribe, take and pay for.
Combinations expand the frontier on efficacy and tolerability
Combination-mechanism programs such as CagriSema and amycretin, a single Novo Nordisk molecule that acts on both GLP-1 and amylin receptors, attempt diagonal expansion. They aim to preserve or add efficacy while differentiating on tolerability, durability or muscle sparing, even if access improves only marginally.
These are examples of strategic direction, not predictions of winners. Frontier expansion does not require majority market share: assets serving narrower segments can still shape payer dynamics, portfolio strategy and capital allocation.
Asset positions come from Sleuth’s December 2025 analysis of 174 Phase 2 and later obesity assets. This page is a dated snapshot; approvals and Medicare coverage are current as of September 2026.
Frequently asked questions about obesity drug value and access
What is the access–efficacy frontier in obesity?
The outer edge of the best combinations of expected efficacy and patient and payer access among the 174 Phase 2 and later obesity assets in Sleuth’s December 2025 analysis. Efficacy combines mechanism class, incretin co-agonism and clinical maturity; access combines route, dosing frequency and inferred cost tier.
Why is access now the main constraint for obesity drugs?
Injectable GLP-1s such as tirzepatide and semaglutide have set a validated efficacy benchmark. In Sleuth’s December 2025 view, a new drug that only beats that benchmark still faces the same payer scrutiny, access friction and incumbent advantages.
Which obesity drugs are pushing the frontier?
In Sleuth’s December 2025 analysis, oral GLP-1s such as orforglipron push toward access, and combination approaches such as CagriSema and amycretin push on efficacy and tolerability. The FDA approved orforglipron as Foundayo on April 1, 2026.
